Novartis CEO: How To Create Cheaper Alternatives To The Most Expensive Drugs

Recently, FDA Commissioner Scott Gottlieb addressed those in attendance at America’s Health Insurance Plans’ (AHIP) National Health Policy Conference. His comments created a lot of visibility around several critical topics, including patient access to innovative treatments, cost-effectiveness, and the role that biosimilars – biologic products that are highly like already-approved and marketed medicines (called reference or originator products) – play in helping deliver access and cost-savings.